



HCPCS Codes Used for Skilled Nursing Facility Consolidated Billing: April 2023 Update

Related CR Release Date: February 9, 2023 MLN Matters Number: MM13089

Effective Date: April 1, 2023

Related Change Request (CR) Number: [CR 13089](#)

Implementation Date: April 3, 2023

Related CR Transmittal Number: R11849CP

Related CR Title: April 2023 Quarterly Update to HCPCS Codes Used for Skilled Nursing Facility (SNF) Consolidated Billing (CB) Enforcement

Affected Providers

- SNFs
- Other providers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients in a covered Medicare Part A stay in a SNF

Action Needed

Make sure your staff knows about:

- Updates to the list of HCPCS codes subject to the CB provision of the SNF Prospective Payment System (PPS)
- Codes for blood clotting factors added to the Medicare Part B SNF files

Background

CMS periodically updates the lists of HCPCS codes that are **excluded** from the CB provision of the SNF PPS. Services **excluded** from SNF PPS and CB may be paid to providers, other than SNFs, for patients, even when in a SNF stay. Medicare won't pay for services not on the **exclusion** lists to any providers other than a SNF.

For non-therapy services, SNF CB applies only when you provide the services to a SNF resident during a covered Part A stay. However, SNF CB applies to physical and occupational therapies and speech-language pathology services whenever provided to a SNF resident, regardless of whether Part A covers the stay. To make sure we make proper payment in all settings, Medicare systems edit for services provided to SNF patients both included and excluded from SNF CB.

Updated [SNF Consolidated Billing Lists](#) are available lists for institutional and professional billing.

Part B File Additions

We've added CPT codes 91316, 91317, 0164A, and 0173A to the Part B SNF CB files for 2018 - 2023, which in part, attempts to reconcile the Part A SNF CB file and the Part B SNF CB files.

The following codes for blood clotting factors were effective October 1, 2021, with the October 2021 quarterly update. The codes weren't added to the Part B SNF CB files for 2022 and 2023. We're adding the codes to the Part B SNF CB File #1 for 2022 and 2023:

- J7170 - INJ., EMICIZUMAB-KXWH 0.5 MG
- J7175 - INJ, FACTOR X, (HUMAN), 1IU
- J7179 - VONVENDI INJ 1 IU VWF:RCO
- J7180 - FACTOR XIII ANTI-HEM FACTOR
- J7181 - FACTOR XIII RECOMB A-SUBUNIT
- J7182 - FACTOR VIII RECOMB NOVOEIGHT
- J7183 - WILATE INJECTION
- J7185 - XYNTHA INJ
- J7186 - ANTIHEMOPHILIC VIII/VWF COMP
- J7187 - HUMATE-P, INJ
- J7188 - FACTOR VIII RECOMB OBIZUR
- J7189 - FACTOR VIIA RECOMB NOVOSEVEN
- J7190 - FACTOR VIII
- J7191 - FACTOR VIII (PORCINE)
- J7192 - FACTOR VIII RECOMBINANT NOS
- J7193 - FACTOR IX NON-RECOMBINANT
- J7194 - FACTOR IX COMPLEX
- J7195 - FACTOR IX RECOMBINANT NOS
- J7196 - ANTITHROMBIN RECOMBINANT
- J7197 - ANTITHROMBIN III INJECTION
- J7198 - ANTI-INHIBITOR
- J7199 - HEMOPHILIA CLOT FACTOR NOC
- J7200 - FACTOR IX RECOMBINAN RIXUBIS
- J7201 - FACTOR IX ALPROLIX RECOMB
- J7202 - FACTOR IX IDELVION INJ
- J7203 - FACTOR IX RECOMB GLY REBINYN
- J7204 - INJ. FACTOR VIII, ANTIHEMOPHILIC FACTOR (RECOMBINANT), (ESPEROCT), GLYCOPEGYLATED-EXEI
- J7205 - FACTOR VIII FC FUSION RECOMB
- J7207 - FACTOR VIII PEGYLATED RECOMB
- J7209 - FACTOR VIII NUWIQ RECOMB 1IU
- J7210 - INJ, AFSTYLA, 1 I.U.
- J7211 - INJ, KOVALTRY, 1 I.U.
- J7212 - FACTOR VIIA RECOMB SEVENFACT

The following code for blood clotting factors was effective July 1, 2021, with the October 2021 quarterly update. The code wasn't added to the Part B SNF CB files for 2022 and 2023. We're adding the code to the Part B SNF CB File #1 for 2021 - 2023:

- Q5123 - INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG

The following HCPCS codes were effective January 9, 2023, and we're adding them to the Part B SNF File #1 for 2023:

- J0892 - ARGATROBAN DIALYSIS (ACCORD)
- J0899 - ARGATROBAN DIALYSIS, AUROMED

The following HCPCS codes were effective January 1, 2023, and we're adding them to processing File #1 for 2023:

- M1187 - PT W/ ESRD
- J0893 - INJ, DECITABINE (SUN PHARMA)
- J9046 - INJ, BORTEZOMIB, DR. REDDY'S
- J9048 - INJ, BORTEZOMIB FRESENIUSKAB
- J9049 - INJ, BORTEZOMIB, HOSPIRA
- J9393 - INJ, FULVESTRANT (TEVA)
- J9394 - INJ, FULVESTRANT (FRESENIUS)
- Q5126 - INJ ALYMSYS 10 MG
- J0893 - INJ, DECITABINE (SUN PHARMA)
- J0891 - ARGATROBAN NONESRD (ACCORD)
- J0898 - ARGATROBAN NONESRD (AUROMED)

The following HCPCS code became effective April 1, 2022, and we're adding it to processing File #1 for 2022:

- J0879 - INJECTION, DIFELIKEFALIN, 0.1 MICROGRAM, (FOR ESRD ON DIALYSIS)

The following HCPCS code became effective July 1, 2019, and we're adding it to processing File #1 for 2019 - 2023:

- J1444 - FE PYRO CIT POW 0.1 MG IRON

File 1 - Deletions

We're removing these HCPCS codes from File #1 effective January 1, 2023:

- C9142 - INJ, ALYMSYS, 10 MG
- J9044 - INJ, BORTEZOMIB, NOS, 0.1 MG

Part A file additions are:**Effective date January 1, 2023, unless otherwise noted.****Major Category III. A. - Chemotherapy**

- J0893 - INJ, DECITABINE (SUN PHARMA)
- J9046 - INJ, BORTEZOMIB, DR. REDDY'S
- J9048 - INJ, BORTEZOMIB FRESENIUSKAB
- J9049 - INJ, BORTEZOMIB, HOSPIRA
- J9393 - INJ, FULVESTRANT (TEVA)
- J9394 - INJ, FULVESTRANT (FRESENIUS)
- Q5126 - INJ ALYMSYS 10 MG

Major Category III. E. - Certain blood clotting factors indicated for the treatment of hemophilia and other bleeding disorders

- J0891 - ARGATROBAN NONESRD (ACCORD)
- J0898 - ARGATROBAN NONESRD (AUROMED)

Major Category IV. B. - Vaccines (Pneumococcal, Flu, Hepatitis B, or COVID-19)

- 91307 - SARSCOV2 VAC 10 MCG TRS-SUCR - effective October 29, 2021
- 91308 - SARSCOV2 VAC 3MCG TRS-SUCR - effective June 17, 2022
- 91309 - SARSCOV2 VAC 50MCG/0.5ML IM - effective March 29, 2022
- 91316 - SARSCOV2 VAC BVL 10MCG/0.2ML - effective December 8, 2022
- 91317 - SARSCOV2 VAC BVL 3MCG/0.2ML - effective December 8, 2022

Major Category IV. C. - Vaccine Administration

- 0034A - ADM SARSCOV2 VAC AD26 .5ML B - effective October 20, 2021
- 0044A - ADM SARSCOV2 5MCG/0.5ML BST - effective October 19, 2021
- 0071A - ADM SARSCV2 10MCG TRS-SUCR 1 - effective October 29, 2021
- 0072A - ADM SARSCV2 10MCG TRS-SUCR 2 - effective October 29, 2021
- 0073A - ADM SARSCV2 10MCG TRS-SUCR 3 - effective January 3, 2022
- 0074A - ADM SARSCV2 10MCG TRS-SUCR B - effective May 17, 2022
- 0081A - ADM SARSCOV2 3MCG TRS-SUCR 1 - effective June 17, 2022
- 0082A - ADM SARSCOV2 3MCG TRS-SUCR 2 - effective June 17, 2022
- 0083A - ADM SARSCOV2 3MCG TRS-SUCR 3 - effective June 17, 2022
- 0094A - ADM SARSCOV2 50MCG/0.5 MLBST - effective March 29, 2022
- 0164A - ADM SRSCV2 BVL 10MCG/0.2ML B - effective December 8, 2022
- 0173A - ADM SARSCV2 BVL 3MCG/0.2ML 3 - effective December 8, 2022

Part A file deletions, effective January 1, 2023**Major Category III. A. - Chemotherapy**

- C9142 - INJ, ALYMSYS, 10 MG
- J9044 - INJ, BORTEZOMIB, NOS, 0.1 MG

More Information

We issued CR 13089 to your MAC as the official instruction for this change.

For more information, [find your MACs' website](#).

Document History

Date of Change	Description
February 9, 2023	Initial article released.

[Medicare Learning Network® Content & Product Disclaimer, and Department of Health & Human Services Disclosure](#)

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).

CPT only copyright 2022 American Medical Association. All rights reserved.